Plasma acylcarnitines are associated with pulmonary hypertension

Nancy Luo, Damian Craig, Olga Ilkayeva, Michael Muehlbauer, William E. Kraus, Christopher B. Newgard, Svati H. Shah, Sudarshan Rajagopal

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Quantifying metabolic derangements in pulmonary hypertension (PH) by plasma metabolomics could identify biomarkers useful for diagnosis and treatment. The objective of this paper is to test the hypotheses that circulating metabolites are differentially expressed in PH patients compared with controls and among different hemodynamic subtypes of PH associated with left heart disease. We studied patients enrolled in the CATHGEN biorepository with PH (right heart catheterization mPAP ≥ 25 mmHg; n = 280). Of these, 133 met criteria for postcapillary PH, 82 for combined precapillary and postcapillary PH (CpcPH), and 65 for precapillary PH. Targeted profiling of 63 metabolites (acylcarnitines, amino acids, and ketones) was performed using tandem flow injection mass spectrometry. Multivariable linear regression was used to determine differences in metabolite factors derived from a principal components analysis between PH cases, PH subtypes, and non-PH controls. In adjusted models, the metabolite factor loaded with long-chain acylcarnitines was higher in all PH cases versus non-PH controls (P = 0.00008), but did not discriminate between CpcPH and postcapillary PH (P = 0.56). In analyses of subtypes, CpcPH patients had lower levels of factors loaded with urea cycle amino acids and short chain acylcarnitines as compared to controls (P = 0.002 and P = 0.01, respectively) and as compared to postcapillary PH (P = 0.04 and P = 0.02, respectively). Compared to controls, PH was strongly associated with greater concentrations of long-chain acylcarnitines. Postcapillary PH and CpcPH were weakly associated with distinct metabolomic profiles. These findings suggest the presence of unique metabolic abnormalities in subtypes of PH and may reflect underlying pathophysiology.

Original languageEnglish (US)
Pages (from-to)211-218
Number of pages8
JournalPulmonary Circulation
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Metabolomics
acylcarnitine
Hypertension
Amino Acids
Cardiac Catheterization
Principal Component Analysis
Ketones
Urea
Linear Models
Heart Diseases
Mass Spectrometry
Biomarkers
Hemodynamics

Keywords

  • Hemodynamics
  • Metabolomics
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Luo, N., Craig, D., Ilkayeva, O., Muehlbauer, M., Kraus, W. E., Newgard, C. B., ... Rajagopal, S. (2017). Plasma acylcarnitines are associated with pulmonary hypertension. Pulmonary Circulation, 7(1), 211-218. https://doi.org/10.1086/690554

Plasma acylcarnitines are associated with pulmonary hypertension. / Luo, Nancy; Craig, Damian; Ilkayeva, Olga; Muehlbauer, Michael; Kraus, William E.; Newgard, Christopher B.; Shah, Svati H.; Rajagopal, Sudarshan.

In: Pulmonary Circulation, Vol. 7, No. 1, 01.01.2017, p. 211-218.

Research output: Contribution to journalArticle

Luo, N, Craig, D, Ilkayeva, O, Muehlbauer, M, Kraus, WE, Newgard, CB, Shah, SH & Rajagopal, S 2017, 'Plasma acylcarnitines are associated with pulmonary hypertension', Pulmonary Circulation, vol. 7, no. 1, pp. 211-218. https://doi.org/10.1086/690554
Luo N, Craig D, Ilkayeva O, Muehlbauer M, Kraus WE, Newgard CB et al. Plasma acylcarnitines are associated with pulmonary hypertension. Pulmonary Circulation. 2017 Jan 1;7(1):211-218. https://doi.org/10.1086/690554
Luo, Nancy ; Craig, Damian ; Ilkayeva, Olga ; Muehlbauer, Michael ; Kraus, William E. ; Newgard, Christopher B. ; Shah, Svati H. ; Rajagopal, Sudarshan. / Plasma acylcarnitines are associated with pulmonary hypertension. In: Pulmonary Circulation. 2017 ; Vol. 7, No. 1. pp. 211-218.
@article{e02795e90ca04168a3f05af33eafe0bd,
title = "Plasma acylcarnitines are associated with pulmonary hypertension",
abstract = "Quantifying metabolic derangements in pulmonary hypertension (PH) by plasma metabolomics could identify biomarkers useful for diagnosis and treatment. The objective of this paper is to test the hypotheses that circulating metabolites are differentially expressed in PH patients compared with controls and among different hemodynamic subtypes of PH associated with left heart disease. We studied patients enrolled in the CATHGEN biorepository with PH (right heart catheterization mPAP ≥ 25 mmHg; n = 280). Of these, 133 met criteria for postcapillary PH, 82 for combined precapillary and postcapillary PH (CpcPH), and 65 for precapillary PH. Targeted profiling of 63 metabolites (acylcarnitines, amino acids, and ketones) was performed using tandem flow injection mass spectrometry. Multivariable linear regression was used to determine differences in metabolite factors derived from a principal components analysis between PH cases, PH subtypes, and non-PH controls. In adjusted models, the metabolite factor loaded with long-chain acylcarnitines was higher in all PH cases versus non-PH controls (P = 0.00008), but did not discriminate between CpcPH and postcapillary PH (P = 0.56). In analyses of subtypes, CpcPH patients had lower levels of factors loaded with urea cycle amino acids and short chain acylcarnitines as compared to controls (P = 0.002 and P = 0.01, respectively) and as compared to postcapillary PH (P = 0.04 and P = 0.02, respectively). Compared to controls, PH was strongly associated with greater concentrations of long-chain acylcarnitines. Postcapillary PH and CpcPH were weakly associated with distinct metabolomic profiles. These findings suggest the presence of unique metabolic abnormalities in subtypes of PH and may reflect underlying pathophysiology.",
keywords = "Hemodynamics, Metabolomics, Pulmonary hypertension",
author = "Nancy Luo and Damian Craig and Olga Ilkayeva and Michael Muehlbauer and Kraus, {William E.} and Newgard, {Christopher B.} and Shah, {Svati H.} and Sudarshan Rajagopal",
year = "2017",
month = "1",
day = "1",
doi = "10.1086/690554",
language = "English (US)",
volume = "7",
pages = "211--218",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "University of Chicago Press",
number = "1",

}

TY - JOUR

T1 - Plasma acylcarnitines are associated with pulmonary hypertension

AU - Luo, Nancy

AU - Craig, Damian

AU - Ilkayeva, Olga

AU - Muehlbauer, Michael

AU - Kraus, William E.

AU - Newgard, Christopher B.

AU - Shah, Svati H.

AU - Rajagopal, Sudarshan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Quantifying metabolic derangements in pulmonary hypertension (PH) by plasma metabolomics could identify biomarkers useful for diagnosis and treatment. The objective of this paper is to test the hypotheses that circulating metabolites are differentially expressed in PH patients compared with controls and among different hemodynamic subtypes of PH associated with left heart disease. We studied patients enrolled in the CATHGEN biorepository with PH (right heart catheterization mPAP ≥ 25 mmHg; n = 280). Of these, 133 met criteria for postcapillary PH, 82 for combined precapillary and postcapillary PH (CpcPH), and 65 for precapillary PH. Targeted profiling of 63 metabolites (acylcarnitines, amino acids, and ketones) was performed using tandem flow injection mass spectrometry. Multivariable linear regression was used to determine differences in metabolite factors derived from a principal components analysis between PH cases, PH subtypes, and non-PH controls. In adjusted models, the metabolite factor loaded with long-chain acylcarnitines was higher in all PH cases versus non-PH controls (P = 0.00008), but did not discriminate between CpcPH and postcapillary PH (P = 0.56). In analyses of subtypes, CpcPH patients had lower levels of factors loaded with urea cycle amino acids and short chain acylcarnitines as compared to controls (P = 0.002 and P = 0.01, respectively) and as compared to postcapillary PH (P = 0.04 and P = 0.02, respectively). Compared to controls, PH was strongly associated with greater concentrations of long-chain acylcarnitines. Postcapillary PH and CpcPH were weakly associated with distinct metabolomic profiles. These findings suggest the presence of unique metabolic abnormalities in subtypes of PH and may reflect underlying pathophysiology.

AB - Quantifying metabolic derangements in pulmonary hypertension (PH) by plasma metabolomics could identify biomarkers useful for diagnosis and treatment. The objective of this paper is to test the hypotheses that circulating metabolites are differentially expressed in PH patients compared with controls and among different hemodynamic subtypes of PH associated with left heart disease. We studied patients enrolled in the CATHGEN biorepository with PH (right heart catheterization mPAP ≥ 25 mmHg; n = 280). Of these, 133 met criteria for postcapillary PH, 82 for combined precapillary and postcapillary PH (CpcPH), and 65 for precapillary PH. Targeted profiling of 63 metabolites (acylcarnitines, amino acids, and ketones) was performed using tandem flow injection mass spectrometry. Multivariable linear regression was used to determine differences in metabolite factors derived from a principal components analysis between PH cases, PH subtypes, and non-PH controls. In adjusted models, the metabolite factor loaded with long-chain acylcarnitines was higher in all PH cases versus non-PH controls (P = 0.00008), but did not discriminate between CpcPH and postcapillary PH (P = 0.56). In analyses of subtypes, CpcPH patients had lower levels of factors loaded with urea cycle amino acids and short chain acylcarnitines as compared to controls (P = 0.002 and P = 0.01, respectively) and as compared to postcapillary PH (P = 0.04 and P = 0.02, respectively). Compared to controls, PH was strongly associated with greater concentrations of long-chain acylcarnitines. Postcapillary PH and CpcPH were weakly associated with distinct metabolomic profiles. These findings suggest the presence of unique metabolic abnormalities in subtypes of PH and may reflect underlying pathophysiology.

KW - Hemodynamics

KW - Metabolomics

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=85034574471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034574471&partnerID=8YFLogxK

U2 - 10.1086/690554

DO - 10.1086/690554

M3 - Article

AN - SCOPUS:85034574471

VL - 7

SP - 211

EP - 218

JO - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 1

ER -